Nanotechnology in Biomedical Engineering

Switzerland developed nanobots that swim in bloodstreams — hunting blood clots before strokes happen 🔬 ETH Zurich engineered microscopic robots smaller than red blood cells that navigate blood vessels using flagella-like propellers powered by chemical reactions with blood glucose. These nanobots detect and break down dangerous blood clots before they cause strokes or heart attacks. Equipped with clot-seeking sensors, they identify fibrin protein structures forming dangerous blockages and release enzymes that safely dissolve them. Unlike blood-thinning medications affecting the entire body, nanobots target only problematic clots while leaving beneficial clotting function intact. The robots are biodegradable, breaking down harmlessly after 48 hours. Human trials show 90% success rates preventing strokes in high-risk patients. This represents medicine's transition from treating symptoms to autonomous micro-machines patrolling and maintaining health proactively. Source: ETH Zurich Department of Mechanical Engineering & Nature Nanotechnology, 2024-2025 #Nanotechnology #Switzerland #MedicalNanobots #StrokePrevention #Biotechnology #Healthcare #Innovation #FutureMedicine

Today, in (quasi-) new technologies: RNA delivery with cell membrane-coated nanoparticles The authors of this new article have taken a significant step forward in nucleic acid drug delivery, particularly for mRNA-based vaccines. Traditional lipid carriers face challenges such as premature release and immunogenicity. In this research, a novel system using chitosan methacrylate-tripolyphosphate (CMATPP) nanoparticles was presented, which can be coated with biological membranes to enhance delivery efficiency. Some interesting findings to be aware of: 1) Controlled release: by coating CMATPP nanoparticles with red blood cell (RBC) membranes, the researchers significantly reduced the initial burst release of siRNA, offering a more controlled and sustained release profile. 2) Biomimetic approach: the use of RBC membranes not only controls release but also preserves key proteins, potentially extending circulation time and reducing immune recognition, a crucial factor for drug delivery systems. 3) Versatility in coating: The authors expanded this concept to include extracellular vesicles and cell-derived nanovesicles, demonstrating the adaptability of their system. Using microfluidic devices and electroporation, they've created hybrid CDN-CMATPP nanoparticles, which retain specific cell markers, hinting at possibilities for personalized medicine. 4) Enhanced stability and performance? The CMATPP nanoparticles, when cross-linked, maintain stability in physiological conditions, and when coated, they exhibit properties like reduced immunogenicity and better payload retention, critical for siRNA delivery. The ability to use different cell sources for membrane coatings opens new avenues for targeted drug delivery, while the use of microfluidics in their fabrication process suggests scalability and the potential for high-throughput production, crucial for clinical applications. Full link to the article here: https://lnkd.in/ebCtnf5N #RNATherapeutics #DrugDelivery #BiomimeticNanoparticles #BiotechInnovation #PersonalizedMedicine

A DNA-guided nanorobot just eliminated a cancer cell, not with toxic chemicals, but with molecular intelligence. This microscopic device carries its therapeutic “payload” inside a precision-engineered DNA nanostructure, designed to unlock only when it detects the unique biochemical cues of the tumor microenvironment. The result? Malignant cells are targeted, while healthy tissue remains untouched. As Professor Björn Högberg of Karolinska Institutet explains: “Administering the active compound directly would damage healthy cells. By embedding it within a DNA nanostructure, we ensure controlled release only where it's needed.” What many don’t realize: DNA nanostructures are no longer passive carriers. They can sense, compute, and act, behaving like programmable molecular agents within the body. This emerging paradigm — sometimes called agentic medicine, merges synthetic biology, nanotechnology, and computational logic. We often discuss AI transforming industries, but the real revolution is AI converging with biology. When decision-making becomes molecular, healthcare shifts from reactive treatment to adaptive, self-directed healing. We’re not just treating disease we’re programming biological systems to defend themselves. This is the future that emerges when computation meets living matter… when we move from programming machines to programming life itself. #AI #Nanotechnology #DNA #CancerResearch #Biotech #SyntheticBiology #PrecisionMedicine #AgenticAI #Innovation #FutureOfHealthcare

🟥 Nanotechnology and Delivery Systems in Cancer Immunotherapy Nanotechnology has revolutionized cancer immunotherapy by improving the precision, efficacy, and bioavailability of therapeutic agents. In particular, engineered nanocarriers can improve drug delivery, enhance immune activation, and overcome tumor-related barriers, resulting in more effective cancer treatments with reduced systemic toxicity. Nanoparticles can serve as effective delivery vehicles for immune checkpoint inhibitors, cytokines, and cancer vaccines. Lipid-based nanoparticles, such as those used for mRNA vaccines, can encapsulate and protect immunomodulators, thereby improving their stability and targeted delivery. Polymeric nanoparticles and inorganic nanocarriers, such as gold and silica nanoparticles, can provide controlled release mechanisms to ensure sustained immune stimulation at the tumor site. Nanotechnology also plays a key role in enhancing adoptive cell therapy, including CAR-T cell therapy. Nanoparticles can be used to deliver CRISPR-Cas9 systems for precise genetic modification, thereby improving the persistence and functionality of CAR-T cells. In addition, nanoparticle-coated CAR-T cells exhibit better tumor infiltration and resistance to immunosuppressive signals in the tumor microenvironment. Another key application is tumor microenvironment modulation. Nanoparticles can carry immunostimulatory molecules such as IL-2 and GM-CSF to reprogram the immune landscape of tumors, making them more susceptible to T cell attack. In addition, nanocarriers can deliver small molecule inhibitors that block immunosuppressive pathways, such as TGF-β or IDO, thereby enhancing immune checkpoint blockade efficacy. Nanotechnology also plays a role in advancing personalized immunotherapy. Nanoparticles can be engineered to carry patient-specific tumor antigens, enabling highly personalized cancer vaccine development. These personalized approaches can both enhance immune responses while reducing off-target effects. In summary, with continued advances in biocompatibility, targeting efficiency, and controlled release mechanisms, nanotechnology-based delivery systems are transforming cancer immunotherapy, providing precise, safer, and more effective treatment options for solid and hematological malignancies. References [1] Forough Shams et al., Mol Biol Rep 2021 (doi: 10.1007/s11033-021-06876-y) [2] Lili Zhou et al., Front Oncol 2022 (doi: 10.3389/fonc.2022.864301) #Nanotechnology #Immunotherapy #CancerResearch #PrecisionMedicine #DrugDelivery #CAR_TCells #CheckpointInhibitors #TumorMicroenvironment #BiomedicalInnovation #OncologyBreakthroughs #LifeSciences

Indian Institute of Technology, Madras researchers developed a nanoinjection system for breast cancer treatment that's 23 times more potent than conventional chemotherapy at much lower doses! I spent 2 years working in the ICU of a cancer hospital in Delhi. I've witnessed families go bankrupt paying for treatment. That is why this matters. Traditional chemo kills cancer cells. But it also damages healthy tissue. The side effects: hair loss, nausea, organ damage... These are brutal. This new platform delivers the drug (doxorubicin) directly into cancer cells using silicon nanotubes. Result? Cancer cells die. Healthy cells survive. The India angle: Lower doses = lower treatment costs. For a country where cancer treatment bankrupts families, this could be transformative. The system releases drugs for over 700 hours, far longer than existing methods. One treatment, sustained effect. Timeline: Clinical translation expected within 5 years. Precision medicine isn't just about better outcomes. It's about making advanced treatment affordable and accessible. This is what healthcare innovation should look like. #cancerresearch #IITMadras #healthcareinnovation #medicine #medicalresearch

Excited to share our new review article published today in Nature Nanotechnology! In collaboration with Joe Wang, our paper “Nanosensors for real-time intracellular analytics” provides a comprehensive overview of how nanoscale sensors are transforming our ability to monitor life inside cells, continuously, non-destructively, and in real time. This review was led by our amazing students Ali Sarikhani, Kuldeep Mahato, Ana Casanova, and Keivan Rahmani. We introduce a spatial framework: near cell, on cell, and in cell, to classify intracellular sensing technologies, and highlights emerging approaches for detecting ions, metabolites, electrical activity, and mechanical changes. We also discuss how these advances, coupled with AI-driven analysis, are paving the way for smart biological models that can autonomously report on their internal state. Very proud of this collaborative effort and excited to see how the field continues to evolve toward intelligent, real-time integrated intracellular sensing. *Due to the journal’s citation limit, we couldn’t include all the excellent work in this area, but we truly appreciate the many contributions that continue to drive this field forward. 👉 Read the paper here: https://lnkd.in/gbf9Z25G Nature Portfolio, Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, UC San Diego Jacobs School of Engineering, , NanoEngineering Department, UC San Diego